22 feb: Aktietilbagekøbsprogram i SP Group A/S
22 feb: Udtrækning pr. 1. april 2019 (CK95)
22-02-2019 06:20:16

Announcement no. 2/2019 - Share Buyback Programme

Announcement no. 2/2019

22 February 2019

Coloplast initiates the second part of the DKK 1bn share buy-back programme

Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, cf. announcement no. 3/2018 of 20 February 2018. The second part of the programme of DKK 500 million will commence on 25 February 2019 and is expected to end by 23 August 2019. The first part of the programme, amounting to DKK 500 million, was executed in the 2017/18 fiscal year.

The buy-back programme is being launched within the authority granted by the shareholders at the Annual General Meeting on 5 December 2018, for the repurchase of up to 10% of the company’s share capital.

The buy-back programme will be structured in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Regulation 2016/1052, also referred to as the "Safe Harbour" rules, which ensure that the company is protected against violation of insider legislation in connection with the buyback programme.

The company has entered into a contract with Nordea, in which Nordea agrees to act as manager of the second part of the buy-back programme for DKK 500 million, and purchase shares on behalf of Coloplast A/S. Nordea has also agreed under the contract to make its trading decisions in relation to the shares in the company independently of, and without influence by, the company.

Coloplast is entitled to discontinue the repurchase during the life of the buy-back programme. If the company decides to discontinue the repurchase, such a decision will be disclosed to the public by announcement to Nasdaq Copenhagen. Once effective, Nordea will no longer be entitled to purchase shares in Coloplast A/S on behalf of the company.

The second part of the buy-back programme is subject to the following terms:

  • The programme will commence on 25 February 2019 and is expected to end by 23 August 2019. 
  • The volume of trading in own shares will be limited to a maximum total market value of DKK 500 million.
  • The maximum number of shares to be purchased in the company per daily market session will be the equivalent to 25% of the average volume of shares in the company traded on Nasdaq Copenhagen during the preceding 20 business days.
  • During the life of the buy-back programme no shares will be purchased at a price exceeding the higher of the following two prices:

i) the price of the last independent trade and

ii) the highest current independent bid on Nasdaq Copenhagen.

Details of transactions executed under the buy-back programme will be publicly disclosed on www.coloplast.com no later than the end of the seventh daily market session.

Prior to the launch of the share buy-back programme Coloplast’s holds 3,510,304 treasury shares, equal to 1.6% of the company’s share capital.

Anders Lonning-Skovgaard

CFO

For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel. +45 4911 1111

Ellen Bjurgert

Vice President, Investor Relations

Tel. +45 4911 1800 / 4911 3376

E-mail dkebj@coloplast.com

Rasmus Sørensen

Senior Manager, Investor Relations

Tel. +45 4911 1800 / 4911 1786

E-mail dkraso@coloplast.com

Press and the media

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

Tel. +45 4911 2607

E-mail dklina@coloplast.com

Website

www.coloplast.com

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebæk

Denmark

Business reg. (CVR) no. 69749917 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2019-02 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Interventional Urology, Continence Care and Wound and Skin Care. We operate globally and employ about 12,000 people.

 

Attachment

logo.png

Relateret indhold
11:39 - 
Aktier/middag: Chr. Hansen tynger fortsat C25 med marka..
12 jun - 
Coloplast/Berenberg: Kursridt er besynderligt - mulig m..
12 jun - 
Aktier/åbning: Novo og Ambu dykker efter stigninger - P..
Relateret debat
24 jun - 
Hvor langt skal vi op... kan den virkelig blive ved med..
17 jun - 
Ja den har toppet mener jeg
17 jun - 
Nix! Coloplast kender kun en vej! Det er op.
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Ford vil eliminere 20 pct. af selskabets europæiske arbejdskraft

27-06-2019 13:55:16
Relaterede nyheder
Den amerikanske bilfabrikant Ford vil skære omkring 20 pct. af selskabets europæiske arbejdskraft fra i en restruktureringsplan, som reflekterer bilproducentens udfordringer på det europæiske marked.Det skriver Bloomberg News.Fords restruktureringsplan, som er blevet leveret i små bidder af flere omgange, vil involvere en reduktion af selskabets produktionsfaciliteter i Europa fra 24 i begyndelsen..

Aktier/åbning: Chr. Hansen falder tungt og trækker C25 med ned

27-06-2019 09:10:58
Et stort kursfald til Chr. Hansen præger den danske aktieåbning torsdag, efter at ingredienskoncernen onsdag aften uventet nedjusterede forventningerne til regnskabsåret 2018/19.Efter fem minutters handel er Chr. Hansens aktie faldet 14,7 pct. til 617,20 kr., og det vægter tungt i C25-indekset, som ligger 1 pct. lavere i 1114,21 - dog også efter fald i 15 af de øvrige aktier i indekset.Chr. Hansen..

Citigroup sænker Carlsberg-anbefaling

27-06-2019 07:49:00
Det amerikanske finanshus Citigroup har sænket anbefalingen af Carlsberg-aktien til "sælg".Det skriver Bloomberg News, der dog ikke oplyser, hvordan anbefalingen var tidligere.Citi vurderer i kommentaren, at sårbarheden i Carlsbergs aktiekurs stiger, da momentum i indtjeningen falmer. Finanshuset vurderer også, at der er vejrrelaterede problemer på nøglemarkederne i Europa og stigende konkurrence ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/Saxo Bank: Novo Nordisk har været en af eliteindeksets vindere
2
ABG om Ambu: Topchefs køb af aktier sender et godt signal til markedet
3
Aktier/tendens: Chr. Hansen ses i strid modvind fra åbningen
4
Onsdagens aktier: Ambu glimtede i toppen mens Nilfisk blev straffet
5
Trump ser "mulig" handelsaftale på G20

Relaterede aktiekurser

Coloplast B A/S 734,80 -0,9% Fald i aktiekurs
Coloplast 109,85 1,9% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. juni 2019 14:38:28
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-27 14:38:28 - 2019-06-27 14:38:28 - 1 - Website: OKAY